Citation of this article
Corresponding Author of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Number of Hits and Downloads for This Article
- Total Article Views (3096)
All Articles published online
|
Nov 21, 2007 (publication date) through Nov 20, 2024
Times Cited of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
| For: | Chen LB, Xu JY, Yang Z, Wang GB. Silencing SMYD3 in hepatoma demethylates RIZI promoter induces apoptosis and inhibits cell proliferation and migration. World J Gastroenterol 2007; 13(43): 5718-5724 [PMID: 17963297 DOI: 10.3748/wjg.v13.i43.5718] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v13/i43/5718.htm |
| Number | Citing Articles |
| 1 |
Liangliang Xu, Peng Wang, Xinfu Feng, Jianwei Tang, Lian Li, Xiaobo Zheng, Jinfu Zhang, Yitao Hu, Tian Lan, Kefei Yuan, Yanfang Zhang, Shengsheng Ren, Xiangyong Hao, Ming Zhang, Mingqing Xu. SETD3 is regulated by a couple of microRNAs and plays opposing roles in proliferation and metastasis of hepatocellular carcinoma. Clinical Science 2019; 133(20): 2085 doi: 10.1042/CS20190666
|
| 2 |
Laith N. AL-Eitan, Doaa M. Rababa'h. Correlation between a variable number tandem repeat (VNTR) polymorphism in SMYD3 gene and breast cancer: A genotype-phenotype study. Gene 2020; 728: 144281 doi: 10.1016/j.gene.2019.144281
|
| 3 |
Yong Liu, Xuegang Luo, Jingyu Deng, Yuan Pan, Li Zhang, Han Liang. SMYD3 overexpression was a risk factor in the biological behavior and prognosis of gastric carcinoma. Tumor Biology 2015; 36(4): 2685 doi: 10.1007/s13277-014-2891-z
|
| 4 |
Heyun Zhang, Zhangyu Zheng, Rongqin Zhang, Yongcong Yan, Yaorong Peng, Hua Ye, Lehang Lin, Junyao Xu, Wenbin Li, Pinbo Huang. SMYD3 promotes hepatocellular carcinoma progression by methylating S1PR1 promoters. Cell Death & Disease 2021; 12(8) doi: 10.1038/s41419-021-04009-8
|
| 5 |
Aijun Liu, Yifan Liu, Bin Li, Ming Yang, Yang Liu, Junwu Su. Role of miR‐223‐3p in pulmonary arterial hypertension via targeting ITGB3 in the ECM pathway. Cell Proliferation 2019; 52(2) doi: 10.1111/cpr.12550
|
| 6 |
Cinzia Bottino, Alessia Peserico, Cristiano Simone, Giuseppina Caretti. SMYD3: An Oncogenic Driver Targeting Epigenetic Regulation and Signaling Pathways. Cancers 2020; 12(1): 142 doi: 10.3390/cancers12010142
|
| 7 |
Ioannis Anestopoulos, Georgia Persephoni Voulgaridou, Alexandros G. Georgakilas, Rodrigo Franco, Aglaia Pappa, Mihalis I. Panayiotidis. Epigenetic therapy as a novel approach in hepatocellular carcinoma. Pharmacology & Therapeutics 2015; 145: 103 doi: 10.1016/j.pharmthera.2014.09.005
|
| 8 |
Filipa Quintela Vieira, Pedro Costa-Pinheiro, Diogo Almeida-Rios, Inês Graça, Sara Monteiro-Reis, Susana Simões-Sousa, Isa Carneiro, Elsa Joana Sousa, Maria Inês Godinho, Fátima Baltazar, Rui Henrique, Carmen Jerónimo. SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3. Oncotarget 2015; 6(15): 13644 doi: 10.18632/oncotarget.3767
|
| 9 |
Honggen Liu, Yong Liu, Fanming Kong, Wen Xin, Xiaojiang Li, Han Liang, Yingjie Jia. Elevated Levels of SET and MYND Domain-Containing Protein 3 Are Correlated with Overexpression of Transforming Growth Factor-β1 in Gastric Cancer. Journal of the American College of Surgeons 2015; 221(2): 579 doi: 10.1016/j.jamcollsurg.2015.02.023
|
| 10 |
Shinnosuke Suzuki, Yusuke Nozawa, Satoshi Tsukamoto, Takehito Kaneko, Hiroshi Imai, Naojiro Minami. Histone methyltransferase Smyd3 regulates early embryonic lineage commitment in mice. REPRODUCTION 2015; 150(1): 21 doi: 10.1530/REP-15-0019
|
| 11 |
Ting-Ting Liu, Hui Xu, Wei-Ping Gao, Shu-Xiang Zhang, Xu-Hong Zhou, Juan Tang, Qiong-Na Liu. SET and MYND Domain-Containing Protein 3 (SMYD3) Polymorphism as a Risk Factor for Susceptibility and Poor Prognosis in Ovarian Cancer. Medical Science Monitor 2016; 22: 5131 doi: 10.12659/MSM.898095
|
| 12 |
Yong Liu, Jingyu Deng, Xuegang Luo, Yuan Pan, Li Zhang, Rupeng Zhang, Han Liang. Overexpression of SMYD3 was associated with increased STAT3 activation in gastric cancer. Medical Oncology 2015; 32(1) doi: 10.1007/s12032-014-0404-y
|
| 13 |
Filipa Quintela Vieira, Pedro Costa-Pinheiro, João Ramalho-Carvalho, Andreia Pereira, Francisco Duarte Menezes, Luís Antunes, Isa Carneiro, Jorge Oliveira, Rui Henrique, Carmen Jerónimo. Deregulated expression of selected histone methylases and demethylases in prostate carcinoma. Endocrine-Related Cancer 2014; 21(1): 51 doi: 10.1530/ERC-13-0375
|
| 14 |
Ning Guo, Rufu Chen, Zhihua Li, Yonggang Liu, Di Cheng, Quanbo Zhou, Jiajia Zhou, Qing Lin. Hepatitis C virus core upregulates the methylation status of the RASSF1A promoter through regulation of SMYD3 in hilar cholangiocarcinoma cells. Acta Biochimica et Biophysica Sinica 2011; 43(5): 354 doi: 10.1093/abbs/gmr021
|
| 15 |
Jing Li, Yun-Feng Piao, Zheng Jiang, Li Chen, Hai-Bo Sun. Silencing of signal transducer and activator of transcription 3 expression by RNA interference suppresses growth of human hepatocellular carcinoma in tumor-bearing nude mice. World Journal of Gastroenterology 2009; 15(21): 2602-2608 doi: 10.3748/wjg.15.2602
|
| 16 |
Yong Liu, Honggen Liu, Xuegang Luo, Jingyu Deng, Yuan Pan, Han Liang. Overexpression of SMYD3 and matrix metalloproteinase-9 are associated with poor prognosis of patients with gastric cancer. Tumor Biology 2015; 36(6): 4377 doi: 10.1007/s13277-015-3077-z
|
| 17 |
Gurukumari Rajajeyabalachandran, Swetha Kumar, Thanabal Murugesan, Shanthi Ekambaram, Ramya Padmavathy, Sooriya Kumar Jegatheesan, Ramesh Mullangi, Sriram Rajagopal. Therapeutical potential of deregulated lysine methyltransferase SMYD3 as a safe target for novel anticancer agents. Expert Opinion on Therapeutic Targets 2017; 21(2): 145 doi: 10.1080/14728222.2017.1272580
|
| 18 |
Stefan Gradl, Holger Steuber, Joerg Weiske, Magda M. Szewczyk, Norbert Schmees, Stephan Siegel, Detlef Stoeckigt, Clara D. Christ, Fengling Li, Shawna Organ, Megha Abbey, Steven Kennedy, Irene Chau, Viacheslav Trush, Dalia Barsyte-Lovejoy, Peter J. Brown, Masoud Vedadi, Cheryl Arrowsmith, Manfred Husemann, Volker Badock, Marcus Bauser, Andrea Haegebarth, Ingo V. Hartung, Carlo Stresemann. Discovery of the SMYD3 Inhibitor BAY-6035 Using Thermal Shift Assay (TSA)-Based High-Throughput Screening. SLAS Discovery 2021; 26(8): 947 doi: 10.1177/24725552211019409
|
| 19 |
Lydia Hopp, Lilit Nersisyan, Henry Löffler-Wirth, Arsen Arakelyan, Hans Binder. Epigenetic Heterogeneity of B-Cell Lymphoma: Chromatin Modifiers. Genes 2015; 6(4): 1076 doi: 10.3390/genes6041076
|
| 20 |
Longji Wu, Jing Huang, Pankaj Trivedi, Xuerong Sun, Hongbing Yu, Zhiwei He, Xiangning Zhang. Zinc finger myeloid Nervy DEAF-1 type (ZMYND) domain containing proteins exert molecular interactions to implicate in carcinogenesis. Discover Oncology 2022; 13(1) doi: 10.1007/s12672-022-00597-9
|
| 21 |
SHANG-WEN DONG, HAO ZHANG, BAO-LI WANG, PEI SUN, YUAN-GUO WANG, PENG ZHANG. Effect of the downregulation of SMYD3 expression by RNAi on RIZ1 expression and proliferation of esophageal squamous cell carcinoma. Oncology Reports 2014; 32(3): 1064 doi: 10.3892/or.2014.3307
|
| 22 |
Antonis Giakountis, Panagiotis Moulos, Michalis E. Sarris, Pantelis Hatzis, Iannis Talianidis. Smyd3-associated regulatory pathways in cancer. Seminars in Cancer Biology 2017; 42: 70 doi: 10.1016/j.semcancer.2016.08.008
|
| 23 |
Shaodan Liu, Ziyue Sun, Yonghui Zhong, Qingxin Cui, Xuegang Luo, Yujie Dai. Advances in Applied Biotechnology. Lecture Notes in Electrical Engineering 2015; 332: 399 doi: 10.1007/978-3-662-45657-6_42
|
| 24 |
Yu Wang, Bin-hui Xie, Wei-hao Lin, Yong-hui Huang, Jia-yan Ni, Jie Hu, Wei Cui, Jun Zhou, Long Shen, Lin-feng Xu, Fan Lian, He-ping Li. Amplification of SMYD3 promotes tumorigenicity and intrahepatic metastasis of hepatocellular carcinoma via upregulation of CDK2 and MMP2. Oncogene 2019; 38(25): 4948 doi: 10.1038/s41388-019-0766-x
|
| 25 |
Lian Yang, Jun He, Libo Chen, Guobin Wang. Hepatitis B virus X protein upregulates expression of SMYD3 and C-MYC in HepG2 cells. Medical Oncology 2009; 26(4): 445 doi: 10.1007/s12032-008-9144-1
|
| 26 |
Michael J. Thomenius, Jennifer Totman, Darren Harvey, Lorna H. Mitchell, Thomas V. Riera, Kat Cosmopoulos, Alexandra R. Grassian, Christine Klaus, Megan Foley, Elizabeth A. Admirand, Haris Jahic, Christina Majer, Tim Wigle, Suzanne L. Jacques, Jodi Gureasko, Dorothy Brach, Trupti Lingaraj, Kip West, Sherri Smith, Nathalie Rioux, Nigel J. Waters, Cuyue Tang, Alejandra Raimondi, Michael Munchhof, James E. Mills, Scott Ribich, Margaret Porter Scott, Kevin W. Kuntz, William P. Janzen, Mikel Moyer, Jesse J. Smith, Richard Chesworth, Robert A. Copeland, P. Ann Boriack-Sjodin, Luis M. Schang. Small molecule inhibitors and CRISPR/Cas9 mutagenesis demonstrate that SMYD2 and SMYD3 activity are dispensable for autonomous cancer cell proliferation. PLOS ONE 2018; 13(6): e0197372 doi: 10.1371/journal.pone.0197372
|
| 27 |
Chuanchao He, Junyao Xu, Jianlong Zhang, Dan Xie, Hua Ye, Zhiyu Xiao, Muyan Cai, Kang Xu, Yunjie Zeng, Haigang Li, Jie Wang. High expression of trimethylated histone H3 lysine 4 is associated with poor prognosis in hepatocellular carcinoma. Human Pathology 2012; 43(9): 1425 doi: 10.1016/j.humpath.2011.11.003
|
| 28 |
ZHEN QU, YONG JIANG, HUAN LI, DE-CAI YU, YI-TAO DING. Detecting abnormal methylation of tumor suppressor genes GSTP1, P16, RIZ1, and RASSF1A in hepatocellular carcinoma and its clinical significance. Oncology Letters 2015; 10(4): 2553 doi: 10.3892/ol.2015.3536
|
| 29 |
Rozenn Josse, Julie Dumont, Alain Fautrel, Marie-Anne Robin, André Guillouzo. Identification of early target genes of aflatoxin B1 in human hepatocytes, inter-individual variability and comparison with other genotoxic compounds. Toxicology and Applied Pharmacology 2012; 258(2): 176 doi: 10.1016/j.taap.2011.10.019
|
| 30 |
Mai Thanh Binh, Nghiem Xuan Hoan, Dao Phuong Giang, Hoang Van Tong, C.-Thomas Bock, Heiner Wedemeyer, Nguyen Linh Toan, Mai Hong Bang, Peter G. Kremsner, Christian G. Meyer, Le Huu Song, Thirumalaisamy P. Velavan. Upregulation of SMYD3 and SMYD3 VNTR 3/3 polymorphism increase the risk of hepatocellular carcinoma. Scientific Reports 2020; 10(1) doi: 10.1038/s41598-020-59667-z
|
| 31 |
Paola Sanese, Candida Fasano, Cristiano Simone. Playing on the Dark Side: SMYD3 Acts as a Cancer Genome Keeper in Gastrointestinal Malignancies. Cancers 2021; 13(17): 4427 doi: 10.3390/cancers13174427
|
| 32 |
Fujia Lin, Danjuan Wu, Dan Fang, Yao Chen, Haitao Zhou, Caiwen Ou. STAT3-induced SMYD3 transcription enhances chronic lymphocytic leukemia cell growth in vitro and in vivo. Inflammation Research 2019; 68(9): 739 doi: 10.1007/s00011-019-01257-5
|
| 33 |
Sotirios C. Kampranis, Philip N. Tsichlis. . Advances in Cancer Research 2009; 102: 103 doi: 10.1016/S0065-230X(09)02004-1
|
| 34 |
Carol-Ann Eberle, Margarita Zayas, Alexey Stukalov, Andreas Pichlmair, Gualtiero Alvisi, André C. Müller, Keiryn L. Bennett, Ralf Bartenschlager, Giulio Superti-Furga. The lysine methyltransferase SMYD3 interacts with hepatitis C virus NS5A and is a negative regulator of viral particle production. Virology 2014; : 34 doi: 10.1016/j.virol.2014.05.016
|